FINWIRES · TerminalLIVE
FINWIRES

$NTRA

15 stories mentioning NTRAUpdated 21d ago

Every FINWIRES story that references NTRA, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday

Healthcare stocks were mixed pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.6%.Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) said a phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, failed to meet the primary efficacy endpoint. Shares of Astrazeneca were down more than 7% and Ionis Pharmaceuticals stock fell past 19% premarket.Greenwich LifeSciences (GLSI) shares were up more than 7% after the company said the European Medicines Agency cleared the use of commercially manufactured GP2 in a phase 3 trial evaluating GLSI-100 to prevent breast cancer recurrence in Europe.Natera (NTRA) said its Signatera molecular residual disease test received European Union In Vitro Diagnostic Regulation Class C certification for use across multiple solid tumor types. Shares of Natera were down more than 1% pre-bell.

$AZN$GLSI$IBB$IONS$NTRA$XLV
Wire

Natera, Aveta Biomics Launch Partnership to Support Phase 3 APG-157 Trial in Head, Neck Cancer

Natera (NTRA) said Monday it is launching a partnership with Aveta Biomics to support AVTA 30-01, Aveta's phase 3 trial assessing APG-157 to treat locally advanced head and neck squamous cell carcinoma.The trial will use Natera's Signatera testing to evaluate molecular residual disease and treatment response during therapy and follow-up, the company said.About 826 patients are expected to be enrolled in North America, Europe, Asia Pacific, and Australia, the company said, adding the trial is slated to start enrollment in H2.Price: $266.00, Change: $+4.09, Percent Change: +1.56%

$NTRA
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.07% higher and the iShares Biotechnology ETF (IBB) flat.Absci (ABSI) stock was up more than 28% after the company priced its underwritten offering of 13.5 million shares at $7.41 each, expecting to raise $100 million in gross proceeds. The financing includes participation from Eli Lilly (LLY), Absci said.Natera (NTRA) shares were up more than 3% after the company said it has secured regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency for its Signatera molecular residual disease, or MRD, test for use in patients with colorectal cancer.ADC Therapeutics (ADCT) stock was down more than 2% after the company said it will reduce its global workforce by about 17% as it shifts resources toward the Zynlonta franchise and seeks operational efficiencies.

$ABSI$ADCT$IBB$NTRA$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as AI Spending Concerns Weigh on Technology Shares

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 1.4%, and the actively traded Invesco QQQ Trust (QQQ) retreated 3% in recent Tuesday premarket activity, amid a broad technology selloff fueled by concerns over borrowing costs and heavy spending on artificial intelligence infrastructure.US stock futures were also lower, with S&P 500 Index futures down 1.4%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures retreating 3% before the start of regular trading.The S&P Global flash readings for June manufacturing and services conditions are due to be released at 9:45 am ET.The state-level unemployment data for May and the Richmond Fed's services and manufacturing readings for June will be released at 10:00 am ET.In premarket action, bitcoin was down by 4.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 3.4% lower, Ether ETF (EETH) retreated by 5.5%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 3.8%, and the iShares US Technology ETF (IYW) was 3.5% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 3.4%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 5.8%, while the iShares Semiconductor ETF (SOXX) fell by 7%.International Business Machines (IBM) shares were up more than 4% in recent premarket activity after the company said it joined the OpenAI Daybreak Cyber Partner program.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) was down 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) retreated by 1.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% higher.Robinhood Markets (HOOD) shares traded down 5.6% in early hours activity after the online investment platform priced a private $2 billion offering of non-interest-bearing senior convertible notes, due Oct. 1, 2029.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 1.5%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was gaining by 0.2%, and the iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.9%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) retreated by 0.6%.Tesla (TSLA) shares were down 2.7% pre-bell, following a 1.1% gain at the previous day's close. NatPower said it has signed a multiyear supply and execution deal with Tesla for more than 25 gigawatt-hours of battery energy storage systems in Italy and the UK.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.7%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) was up 2%. The iShares Biotechnology ETF (IBB) was down 0.7%.Natera (NTRA) stock was down more than 2% premarket, extending the 1.1% decline at the prior close. The company said it has received a Category 1 recommendation from the National Comprehensive Cancer Network for Signatera-guided adjuvant atezolizumab treatment in patients with muscle-invasive bladder cancer.EnergyThe iShares US Energy ETF (IYE) was down 0.03%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.2%.Energy Fuels (UUUU) stock was down more than 2% before market open after the company agreed to acquire Germany's Vaccumschmelze and associated business and subsidiaries from Ara Partners for $1.9 billion in cash and stock.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) declined by 1.2%, while the Vanguard Industrials Index Fund (VIS) was up less than 0.1% and the iShares US Industrials ETF (IYJ) was flat.A. O. Smith (AOS) stock little changed before the opening bell. The company said its board has elected Stephen Shafer, president and chief executive officer, as chairman, effective July 1, after Executive Chairman Kevin Wheeler retires.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.3% to $73.60 per barrel on the New York Mercantile Exchange. Natural gas was down by 1.6% to $3.20 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 1%, while the United States Natural Gas Fund (UNG) was 1.5% lower.Gold futures for July were down by 1.6% to $4,134.70 an ounce on the Comex. Silver futures retreated by 5.1% to $62.21 an ounce. SPDR Gold Shares (GLD) declined by 2%, and the iShares Silver Trust (SLV) was 4.9% lower.

Dow JonesNasdaq CompositeS&P 500$AOS$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$HOOD$IBB$IBM$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NTRA$PMR$QQQ$RTH$SLV$SOXX$SPY$TSLA$UNG$USO$UUUU$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday

Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) 0.7% lower.Natera (NTRA) has received a Category 1 recommendation from the National Comprehensive Cancer Network for Signatera-guided adjuvant atezolizumab treatment in patients with muscle-invasive bladder cancer, the company said. Natera shares were down more than 2% premarket.Boundless Bio (BOLD) stock was up more than 79% after the company said it signed a definitive merger agreement with privately held biotech firm Serapha Bio in an all-stock merger.Armata Pharmaceuticals (ARMP) shares were up more than 10% after the company said it has received an additional $2.5 million in non-dilutive funding under a previously announced award from the Department of Defense.

$ARMP$BOLD$IBB$NTRA$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) 0.3% lower.Natera (NTRA) has received a Category 1 recommendation from the National Comprehensive Cancer Network for Signatera-guided adjuvant atezolizumab treatment in patients with muscle-invasive bladder cancer, the company said. Natera shares were down more than1% premarket.

$NTRA
Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.Tempus AI (TEM) shares were up more than 6% after the company said it has received approval from the US Food and Drug Administration for a tumor-only indication for its xT CDx next-generation sequencing platform used for comprehensive genomic profiling of solid tumors.Agios Pharmaceuticals (AGIO) stock was down more than 3% after the company said it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a phase 2b study failed to meet the company's threshold for further advancement.Natera (NTRA) shares were up more than 1% after the company said Diakonos Oncology will use its Signatera test to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II investigational immunotherapy trial.

$AGIO$IBB$NTRA$TEM$XLV
Sectors

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the iShares Biotechnology ETF (IBB) 0.4% higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.Natera (NTRA) stock was up more than 2% after the company said it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said. Shares of Jade Biosciences were up more than 5% premarket.

$IBB$JBIO$LLY$NTRA$XLV
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.8%.Roivant Sciences (ROIV) stock was up nearly 6% after the company reported that it swung to a fiscal Q4 net income.ImmunityBio's (IBRX) supplemental biologics license application for Anktiva in combination with Bacillus Calmette-Guerin in patients with bladder cancer with papillary disease has been accepted for review by the US Food and Drug Administration, the company said. ImmunityBio shares were 8% higher pre-bell.Natera (NTRA) stock was up more than 2% after the company said the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.

$IBB$IBRX$NTRA$ROIV$XLV
Wire

Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer

Natera (NTRA) said Friday the US Food and Drug Administration approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab to treat muscle-invasive bladder cancer.The approval follows phase 3 trial results that showed Signatera molecular residual disease-positive patients treated with immunotherapy achieved improvements in disease-free survival and overall survival, while MRD-negative patients achieved 97% two-year OS with no adjuvant therapy, the company said.Price: $189.00, Change: $-7.91, Percent Change: -4.02%

$NTRA
Wire

Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours

Natera (NTRA) reported a Q1 net loss late Thursday of $0.60 per diluted share, widening from the loss of $0.50 a year earlier.Analysts polled by FactSet expected a loss of $0.54.Revenue in the three months ended March 31 rose to $696.6 million from $501.8 million a year earlier.Analysts surveyed by FactSet expected $617.1 million.The company boosted full-year revenue guidance to $2.74 billion to $2.82 billion from the previous forecast of $2.62 billion to $2.70 billion.Analysts expect $2.67 billion.Natera shares fell 4.5% in after-hours trading.

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $693,560, According to a Recent SEC Filing

Solomon Moshkevich, President of Clinical Diagnostics, on May 01, 2026, sold 3,405 shares in Natera (NTRA) for $693,560. Following the Form 4 filing with the SEC, Moshkevich has control over a total of 142,295 common shares of the company, with 142,295 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000201001926000013/xslF345X05/form4-05052026_090506.xml

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing

Steven Leonard Chapman, Director, Chief Executive Officer and President, on April 27, 2026, sold 5,838 shares in Natera (NTRA) for $1,191,775. Following the Form 4 filing with the SEC, Chapman has control over a total of 150,769 common shares of the company, with 150,769 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000171196826000010/xslF345X05/form4-04292026_090410.xml

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $1,001,645, According to a Recent SEC Filing

Michael Burkes Brophy, Chief Financial Officer, on April 27, 2026, sold 5,063 shares in Natera (NTRA) for $1,001,645. Following the Form 4 filing with the SEC, Brophy has control over a total of 58,291 common shares of the company, with 58,291 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000169736226000008/xslF345X05/form4-04292026_090402.xml

$NTRA
Research

William Blair Initiates Natera at Outperform

Natera (NTRA) has an average rating of buy and mean price target of $258.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$NTRA

Track with the FINWIRES app suite